What outcomes have been reported for HLA-B*5701-positive patients on nonabacavir regimens for the treatment of HIV?

Updated: Dec 07, 2018
  • Author: Ali Torkamani, PhD; Chief Editor: Karl S Roth, MD  more...
  • Print


Better virologic but not immunologic responses to combination antiretroviral therapy (cART) have been shown in HLA-B*5701-positive patients on nonabacavir regimens. In a British study, HLA-B*5701-positive patients were more likely to achieve viral suppression than negative patients on a nonabacavir regimen (hazard ratio=1.29; 95% confidence interval [CI], 1.15-1.54) and less likely to experience viral rebound (hazard ratio=0.61; 95% CI, 0.37-0.99). [14]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!